表柔比星联合紫杉醇治疗三阴性乳腺癌的临床效果

胡官强，郭莲，黄彩宇，张晓斌*

（富平县医院肿瘤内科，陕西 渭南，711700）

浏览次数：123次 下载次数：336次

摘要：

目的 探讨表柔比星联合紫杉醇治疗三阴性乳腺癌的临床效果。方法 将我院收治的72 例三阴性乳腺癌患者随机分为 试验组和对照组，每组36 例。对照组给予表柔比星治疗，试验组给予表柔比星联合紫杉醇治疗。比较两组患者治疗前、后肿 瘤标志物（CA125、CA153）水平、临床效果及生活质量。结果 治疗后，两组患者的CA125 及CA153 水平明显优于治疗前，且试 验组明显优于对照组（P<0.05）；试验组总有效率为83.33%，明显高于对照组的61.11%（P<0.05）；治疗后，两组患者的SF-36 总评分均升高，且试验组明显高于对照组（P<0.05）。结论 表柔比星联合紫杉醇治疗三阴性乳腺癌，可有效降低肿瘤标志物 水平，具有显著的临床疗效，且能有效提高患者的生活质量。

关键词：三阴性乳腺癌；表柔比星；紫杉醇；肿瘤标志物；生活质量

中图分类号：R737.9 文献标志码：A文章编号：2096-1413(2018)05-0078-02

Clinical effect of epirubicin combined with paclitaxel in the treatment of triple-negative breast cancer
HU Guan-qiang, GUO Lian, HUANG Cai-yu, ZHANG Xiao-bin *
(Oncology Department, the Hospital of Fuping County, Weinan 711700, China)

ABSTRACT: Objective To investigate the clinical effect of epirubicin combined with paclitaxel in the treatment of triple-negative breast cancer. Methods Seventy-two cases of patients with triple-negative breast cancer were randomly divided into experimental group and control group, with 36 cases in each group. The control group was given epirubicin, and the experimental group was treated with epirubicin combined with paclitaxel. The levels of tumor markers ( CA125 and CA153) before and after treatment, clinical effects and quality of life were compared between the two groups. Results After treatment, the levels of CA125 and CA153 of the two groups were better than those before treatment, and those of the experimental group were better than the control group (P<0.05). The total effective rate of the experimental group was 83.33%, which was higher than 61.11% of the control group (P<0.05). After treatment, the total SF-36 scores of the two groups were higher than those before treatment, and that of the experimental group was higher than the control group (P<0.05). Conclusion Epirubicin combined with paclitaxel in the treatment of triple-negative breast cancer can reduce the levels of tumor markers, has significant clinical effect and can improve the patients`` quality of life.
KEYWORDS: triple-negative breast cancer; epirubicin; paclitaxel; tumor marker; quality of life

参考文献：
[1] COUCH FJ,KUCHENBAECKER KB,MICHAILIDOU K,et al.Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer[J].Nat Commun,2016,7:11375.
[2] 侯晓东,尤晓琼.表柔比星联合紫杉醇治疗三阴性乳腺癌的效果研 究[J].中国实用医药,2016,8(32):151-152.
[3] VERA-VILLARROEL P.An appraisal of the SF12 questionnaire (reply)[J].Rev Med Chil,2015,143(7):953-954.
[4] 陈勇,刘华江,赵妍妍,等.紫杉醇联合表柔比星对中晚期乳腺癌患 者的远期疗效与生活质量改善观察[J].白求恩医学杂志,2017,15
(1):66-67.
[5] LOPEZ OG,BEDOYA AD,GUTIERREZ AJ,et al.Relationship between short-form health SF36 questionnaire and oxygen uptake in healthy workers[J].J Sports Med Phys Fitness,2016,56(3):280-286.
[6] 王丽娜,张崇建,李连方,等.三阴性乳腺癌表柔比星和环磷酰胺联合紫杉醇周疗新辅助化疗临床观察[J].中华肿瘤防治杂志,2015,
22(3):211-215.
[7] EISENHAUER EA,THERASSE P,BOGAERTS J,et al.New response
evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[8] 徐丹英,袁雁,李福明.盐酸表柔比星联合卡培他滨片治疗三阴性 乳腺癌患者的临床效果及对血清OPN、VEGF-C 的影响[J].中国 生化药物杂志,2016,36(11):118-120.
[9] 李稳,陈玉娟,汪静.三阴性乳腺癌的临床病理特征及治疗进展[J]. 华西医学,2017,32(2):267-270.
[10] 余韬,李岩.三阴性乳腺癌生存分析及预后影响因素[J].实用肿瘤 杂志,2017,32(1):61-65.
[11] 李光,刘洪霞,刘军.不同剂量表柔比星联合新辅助化疗治疗三阴性乳腺癌的疗效和毒副反应[J].河北医药,2017,39(9):1387-1389.